Resultados de la búsqueda 11-20 of 1501 for SC

  1. Nefrología e hipertensión - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing ...

  2. Centro de Cáncer de Cabeza y Cuello - Ensayos clínicos - Mayo Clinic

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  3. Anafilaxia - Médicos y departamentos - Mayo Clinic

    Mostrando 1-10 de doctores disponibles · Fernanda Bellolio, M.D., M.S. · Kimberly G. Blumenthal, M.D., M.Sc. · Kate M. Freeman, M.B., B.Ch. · John B. Hagan, M.D..

  4. Nefrología e hipertensión - Ensayos clínicos

    Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  6. Nefrología e hipertensión - Ensayos clínicos

    Additionally, to assess the safety of daratumumab SC in treating patients with PGNMID by assessing the incidence of major infections, eye complications, and ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  8. Oncología (médica) - Ensayos clínicos

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...

  9. Oncología (médica) - Ensayos clínicos

    Also, to evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed at 600 mg SC every 3 weeks and doxorubicin dosed at ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. Also, to evaluate safety ...